Colgate-Palmolive and Tom's of Maine $2.9M Settlement Over Alleged Deceptive Toothpaste Marketing

Colgate-Palmolive and its Tom’s of Maine brand are facing a $2.9 million proposed class action settlement tied to allegations that the company engaged in deceptive marketing of toothpaste. The case—**Rabinowitz et al. v. Colgate-Palmolive Company et al. (E.D.N.Y., No. 2:25-cv-6996)**—centers on claims that Tom’s of Maine marketed certain toothpaste in ways consumers understood as accurate, even as the company was allegedly under scrutiny after an **FDA inspection of its Sanford, Maine facility**. The proposed settlement is intended for U.S. consumers who purchased Tom’s of Maine toothpaste during the class period **(Nov. 21, 2020 through Mar. 6, 2026)**, with claim options that appear to include a simplified “without proof” method using household-average pricing and a “with proof” method that allows **full refunds for up to three products**. The lawsuit was filed to give consumers a collective mechanism to seek compensation and to address whether marketing claims were misleading in violation of consumer-protection principles. Its significance lies in the way it spotlights how toothpaste advertising—such as implied benefits or labeling messages—can become a legal issue when regulators or investigators raise concerns about product practices. More broadly, these disputes fit a well-trodden pattern of consumer class actions targeting **“deceptive” health or performance claims** in the over-the-counter health and personal care industries, often echoing similar cases brought under state consumer laws and enforced alongside federal frameworks like FDA oversight of foods, drugs, and cosmetics, including rules that govern **how products are labeled and marketed**. Industry-wise, toothpaste and similar consumer products operate in a tightly regulated environment where manufacturers must ensure advertising is truthful, not misleading, and consistent with how products are regulated. While the settlement is not necessarily a court finding of wrongdoing, it reflects the legal and financial pressure companies face when regulators inspect facilities or when consumers challenge marketing claims as deceptive. For affected consumers, the deadline to **submit claims and to opt out or object is July 6, 2026**, making the process a practical step toward potential refunds while the court reviews final approval at a scheduled **September 10, 2026** hearing—illustrating how advertising, compliance, and enforcement can converge in class litigation when the stakes involve everyday health products.